-
Je něco špatně v tomto záznamu ?
Genetic Testing in Patients with Hypertrophic Cardiomyopathy
J. Bonaventura, E. Polakova, V. Vejtasova, J. Veselka
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články, přehledy
Grantová podpora
grant No. 00064203
Conceptual Development of Research Organization, Motol University Hospital, Prague
grant No. 15-34904A
Ministry of Health of the Czech Republic
NLK
Free Medical Journals
od 2000
Freely Accessible Science Journals
od 2000
PubMed Central
od 2007
Europe PubMed Central
od 2007
ProQuest Central
od 2000-03-01
Open Access Digital Library
od 2000-01-01
Open Access Digital Library
od 2007-01-01
Health & Medicine (ProQuest)
od 2000-03-01
ROAD: Directory of Open Access Scholarly Resources
od 2000
PubMed
34638741
DOI
10.3390/ijms221910401
Knihovny.cz E-zdroje
- MeSH
- genetické testování * MeSH
- hypertrofická kardiomyopatie diagnóza genetika MeSH
- lidé MeSH
- mutace * MeSH
- sarkomery genetika MeSH
- svalové proteiny genetika MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Hypertrophic cardiomyopathy (HCM) is a common inherited heart disease with an estimated prevalence of up to 1 in 200 individuals. In the majority of cases, HCM is considered a Mendelian disease, with mainly autosomal dominant inheritance. Most pathogenic variants are usually detected in genes for sarcomeric proteins. Nowadays, the genetic basis of HCM is believed to be rather complex. Thousands of mutations in more than 60 genes have been described in association with HCM. Nevertheless, screening large numbers of genes results in the identification of many genetic variants of uncertain significance and makes the interpretation of the results difficult. Patients lacking a pathogenic variant are now believed to have non-Mendelian HCM and probably have a better prognosis than patients with sarcomeric pathogenic mutations. Identifying the genetic basis of HCM creates remarkable opportunities to understand how the disease develops, and by extension, how to disrupt the disease progression in the future. The aim of this review is to discuss the brief history and recent advances in the genetics of HCM and the application of molecular genetic testing into common clinical practice.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22003670
- 003
- CZ-PrNML
- 005
- 20220127150007.0
- 007
- ta
- 008
- 220113s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/ijms221910401 $2 doi
- 035 __
- $a (PubMed)34638741
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Bonaventura, Jiri $u Department of Cardiology, Motol University Hospital, 2nd Faculty of Medicine, Charles University, V Uvalu 84, 15006 Prague, Czech Republic
- 245 10
- $a Genetic Testing in Patients with Hypertrophic Cardiomyopathy / $c J. Bonaventura, E. Polakova, V. Vejtasova, J. Veselka
- 520 9_
- $a Hypertrophic cardiomyopathy (HCM) is a common inherited heart disease with an estimated prevalence of up to 1 in 200 individuals. In the majority of cases, HCM is considered a Mendelian disease, with mainly autosomal dominant inheritance. Most pathogenic variants are usually detected in genes for sarcomeric proteins. Nowadays, the genetic basis of HCM is believed to be rather complex. Thousands of mutations in more than 60 genes have been described in association with HCM. Nevertheless, screening large numbers of genes results in the identification of many genetic variants of uncertain significance and makes the interpretation of the results difficult. Patients lacking a pathogenic variant are now believed to have non-Mendelian HCM and probably have a better prognosis than patients with sarcomeric pathogenic mutations. Identifying the genetic basis of HCM creates remarkable opportunities to understand how the disease develops, and by extension, how to disrupt the disease progression in the future. The aim of this review is to discuss the brief history and recent advances in the genetics of HCM and the application of molecular genetic testing into common clinical practice.
- 650 _2
- $a hypertrofická kardiomyopatie $x diagnóza $x genetika $7 D002312
- 650 12
- $a genetické testování $7 D005820
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a svalové proteiny $x genetika $7 D009124
- 650 12
- $a mutace $7 D009154
- 650 _2
- $a sarkomery $x genetika $7 D012518
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Polakova, Eva $u Department of Cardiology, Motol University Hospital, 2nd Faculty of Medicine, Charles University, V Uvalu 84, 15006 Prague, Czech Republic
- 700 1_
- $a Vejtasova, Veronika $u Department of Cardiology, Motol University Hospital, 2nd Faculty of Medicine, Charles University, V Uvalu 84, 15006 Prague, Czech Republic
- 700 1_
- $a Veselka, Josef $u Department of Cardiology, Motol University Hospital, 2nd Faculty of Medicine, Charles University, V Uvalu 84, 15006 Prague, Czech Republic
- 773 0_
- $w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 22, č. 19 (2021)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34638741 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220113 $b ABA008
- 991 __
- $a 20220127150004 $b ABA008
- 999 __
- $a ok $b bmc $g 1751203 $s 1154819
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 22 $c 19 $e 20210927 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
- GRA __
- $a grant No. 00064203 $p Conceptual Development of Research Organization, Motol University Hospital, Prague
- GRA __
- $a grant No. 15-34904A $p Ministry of Health of the Czech Republic
- LZP __
- $a Pubmed-20220113